Mona Ashiya - 08 Jun 2026 Form 4 Insider Report for Shattuck Labs, Inc. (STTK)

Reporting relationship: Director
Issuer ticker: STTK
Reported as of: 08 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2026, 20:56:11 UTC
Prior SEC filing: 02 Jun 2026
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Mona Ashiya

Key filing fact

Mona Ashiya filed Form 4 for Shattuck Labs, Inc. (STTK) on 09 Jun 2026.

Key facts

This page summarizes Mona Ashiya's Form 4 filing for Shattuck Labs, Inc. (STTK).
4 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 09 Jun 2026, 20:56.

Change

Previous filing in this sequence was filed on 02 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001794070 Primary reporting owner

Ashiya Mona

Relationship: Director
Address: C/O SHATTUCK LABS, INC, 500 W 5TH ST., AUSTIN
Signature: /s/ Mona Ashiya
Signature date: 09 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

STTK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 5,255,106
Date: 08 Jun 2026
Ownership: See Footnote
Footnotes: F3, F5

STTK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,051,021
Date: 08 Jun 2026
Ownership: See Footnote
Footnotes: F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

STTK transaction Derivative

Pre-Funded Warrants (right to buy)

Conversion of derivative security

Transaction value
Shares: +15,366,490
Change %: +152%
Price
Shares after: 25,477,874
Date: 08 Jun 2026
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 15,366,490
Exercise price: $0.000100
Footnotes: F1, F2, F3, F5

STTK transaction Derivative

Pre-Funded Warrants (right to buy)

Conversion of derivative security

Transaction value
Shares: +3,073,298
Change %: +152%
Price
Shares after: 5,095,575
Date: 08 Jun 2026
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 3,073,298
Exercise price: $0.000100
Footnotes: F1, F2, F4, F5

STTK transaction Derivative

Common Warrants (right to buy)

Conversion of derivative security

Transaction value
Shares: -15,366,490
Change %: -100%
Price
Shares after: 0
Date: 08 Jun 2026
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 15,366,490
Exercise price: $1.08
Footnotes: F1, F2, F3, F5

STTK transaction Derivative

Common Warrants (right to buy)

Conversion of derivative security

Transaction value
Shares: -3,073,298
Change %: -100%
Price
Shares after: 0
Date: 08 Jun 2026
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 3,073,298
Exercise price: $1.08
Footnotes: F1, F2, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the OrbiMed Private Investments IX, LP ("OPI IX") and OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund") in a private placement which closed on August 25, 2025 (the "Closing Date") an aggregate of 6,306,127 shares of the Issuer's common stock ("Shares") and pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 12,133,661 Shares. OPI IX and Genesis Master Fund also received accompanying common warrants ("Common Warrants") to purchase up to an aggregate of 18,439,799 Shares or, if elected, Pre-Funded Warrants. The price per Share and accompanying Common Warrant were $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant were $0.8676. On June 8, 2026, the Common Warrants were exercised in exchange for Pre-Funded Warrants.

Footnote F2

The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.

Footnote F3

These securities are held of record by OPI IX. OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX.

Footnote F4

These securities are held of record by Genesis Master Fund. OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.

Footnote F5

Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.